Skip Navigation


QJM Advance Access originally published online on January 23, 2007
QJM 2007 100(2):113-119; doi:10.1093/qjmed/hcl139
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/2/113    most recent
hcl139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dasgupta, I.
Right arrow Articles by Burden, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dasgupta, I.
Right arrow Articles by Burden, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

‘Benign’ hypertensive nephrosclerosis

I. Dasgupta1, C. Porter2, A. Innes3 and R. Burden2

From the 1Birmingham Heartlands Hospital, Birmingham, 2Nottingham City Hospital, Nottingham and 3Crosshouse Hospital, Kilmarnock, UK

Address correspondence to Dr I. Dasgupta, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS. email: indranil.dasgupta{at}heartofengland.nhs.uk

Received 7 February 2006 and in revised form 19 October 2006


   Abstract

Background: Whether benign hypertensive nephrosclerosis (BHN) causes end-stage renal failure (ESRF) is controversial. One reason for this is the lack of biopsy evidence confirming the clinical diagnosis in most cases.

Aim: To investigate whether biopsy-proven BHN leads to ESRF.

Design: Retrospective analysis.

Methods: We analysed all cases of biopsy-proven BHN from a single centre over a period of 20 years (n = 60), followed-up for a mean ± SD 6.7 ± 5.5 years.

Results: Patients were divided into those with stable renal function (n = 17) and those with declining function (n = 43). Mean eGFR at the time of biopsy was lower in the declining function group (29 ± 3 vs. 44 ± 4 ml/min/1.73 m2, serum creatinine 280 ± 165 vs. 161 ± 89 µmol/l, p < 0.001), of whom 72% progressed to ESRF. Median renal survival for the whole group was 6.8 years, with 5- and 10-year survivals of 56% and 35%, respectively. Renal survival was significantly affected by initial serum creatinine, and mean systolic and diastolic blood pressures during follow-up period. Mean protein excretion was higher in the declining group, but not significantly so. On multivariate analysis, only diastolic blood pressure during follow-up predicted renal survival (p = 0.017). Median patient survival for the whole group was 9.95 years post renal biopsy, with 5- and 10-year survivals of 70% and 49% respectively. Survival was affected by initial serum creatinine, initial serum albumin and mean systolic blood pressure during follow-up. On multivariate analysis, only initial serum creatinine was significantly correlated with survival (p = 0.017).

Discussion: Biopsy-proven BHN led to ESRF in a high percentage of our patients, and was associated with significant mortality.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.